A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
AIMS Medical Science
Parkinson's disease (PD), similar with other neurodegenerative disorders, would benefit from the identification of early biomarkers for differential diagnosis and prognosis to address prompt clinical treatments. Together with hypothesis driven approaches, PD has been investigated by high-throughput differential proteomic analysis of cerebrospinal fluid (CSF) protein content. The principal methodologies and techniques utilized in the proteomics field for PD biomarker discovery from CSF aredoi:10.3934/medsci.2015.1.1 fatcat:wb2fliwvtvcbznha2s25ggbata